SOHO 2021: Next Questions
By Susan O'Brien, MD, Hagop Kantarjian, MD - Last Updated: November 15, 2022At the ninth annual meeting of the Society of Hematologic Oncology, Susan O’Brien, MD, and Hagop Kantarjian, MD, co-chaired a session addressing next questions and future trends in hematologic malignancies.
Advertisement
Post Tags:SOHO21
Advertisement
Related Posts
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.